EGFR and non-small cell lung carcinoma: A five-state semi-Markov model that predicted improved OS with osimertinib versus the placebo in an adjuvant setting, suggested that the adjuvant osimertinib may increase life expectancy significantly in patients with stage IB-IIIA EGFR-mutant NSCLC compared with the placebo, with a 17.4% absolute improvement in OS at 10 years [29].